Evaluation of the Incidence of Anal Fissures in Patients Who Systemic Isotretinoin Therapy for Acne
Keywords:
acne vulgaris, isotretinoin, adverse events, anal fissure, constipationAbstract
Introduction: Isotretinoin is an effective drug widely used in the treatment of severe acne. In this study, we tried to evaluate the incidence of anal fissures with clinical and laboratory side effects associated with isotretinoin.
Methods: The study evaluated 210 patients who received systemic isotretinoin treatment. Especially patients with constipation and anal bleeding were evaluated by the General Surgery clinic to arrange appropriate treatments.
Results: Of 210 patients included in the study, 138 (65.7%) were female and 72 (34.3%) were male, with a mean age of 23.7 years. The most common adverse event was dry lips in 206 (98.1%) patients. The mucocutaneous side effects were constipation 36 (17.1%), anal bleeding 18 (8.6%), mucosal erosion 10 (4.7%), anal fissure 7 (3.3%). Treatment was discontinued due to elevated liver function tests in 5 patients (2.3%), and because anal bleeding could not be controlled in 1 patient.
Conclusions: Isotretinoin is the most effective acne medicine used today. Clarification of the patients about the rarely seen side effects such as dryness, erosion, fissure and bleeding in the anal mucosa in addition to the common mucocutaneous side effects will ensure that patients are more cautious and increase their tolerance to the treatment.
References
Zaenglein AL, Thiboutot DM. Acne vulgaris. In Bolognia JL, Jorizza JL, Rapini RP, editors. Dermatology. 2nd ed. Spain, Mosby Elsevier Inc 2008:495-508.
Rapp DA, Brenes GA, Feldman SR, et al. Anger and acne: implications for quality of life, patient satisfaction and clinical care. Br J Dermatol. 2004;151(1):183-189. DOI: 10.1111/j.1365-2133.2004.06078.x. PMID: 15270889.
Tom WL, Friedlander SF. Acne through the ages: case-based observations through childhood and adolescence. Clin Pediatr (Phila). 2008;47(7):639-651. DOI: 10.1177/0009922808315444. PMID: 18698096.
Zanglein AL, Graber ME, Thiboutot DM, Strauss JS. Acne vulgaris and acneiform eruptions. In Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York, McGraw Hill. Inc 2008:690-703.
Olutunmbi Y, Paley K, English JC 3rd. Adolescent female acne: etiology and management. J Pediatr Adolesc Gynecol. 2008;;21(4):171-176. DOI: 10.1016/j.jpag.2007.07.004. PMID: 18656070.
Rigopoulos D, Larios G, Katsambas AD: The role of isotretinoin in acne therapy: why not as first-line therapy? Facts and controversies. Clin Dermatol.;28(1):24-30. DOI: 10.1016/j.clindermatol.2009.03.005. PMID: 20082946.
Hodgkiss-Harlow CJ, Eichenfield LF, Dohil MA. Effective monitoring of isotretinoin safety in a pediatric dermatology population: a novel “patient symptom survey” approach. J Am Acad Dermatol. 2011;;65(3):517-524. DOI: 10.1016/j.jaad.2010.06.040. PMID: 21632153. PMCID: PMC4336191.
Lowenstein EB, Lowenstein EJ: Isotretinoin systemic therapy and the shadow cast upon dermatology’s downtrodden hero. Clin Dermatol. 2011;;29(6):652-661. DOI: 10.1016/j.clindermatol.2011.08.026. PMID: 22014987.
Habeshian KA, Cohen BA. Current Issues in the Treatment of Acne Vulgaris. Pediatrics. 2020;145(Suppl 2):S225-S230. DOI: 10.1542/peds.2019-2056L. PMID: 32358215.
Cunliffe WJ, van de Kerkhof PC, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology. 1997;194(4):351-357. DOI: 10.1159/000246134. PMID: 9252756.
Borovaya, A, Dombrowski Y, Zwicker S, et al. Isotretinoin therapy changes the expression of antimicrobial peptides in acne vulgaris. Archives of Dermatological Research. 2014;306(8):689-700. DOI: 10.1007/s00403-014-1477-3. PMID: 24916439.
Li W, Liu Y, Luo Q, Li X-M, Zhang X-B. Off-label uses of retinoids in dermatology. Our Dermatol Online. 2012;3(Suppl. 1):259-278. DOI: 10.7241/ourd.20124.62.
Martin P, Manley PN, Depew WT, Blakeman JM. Isotretinoin-associated proctosigmoiditis. Gastroenterology. 1987;93(3):606-609. DOI: 10.1016/0016-5085(87)90925-5. PMID: 3475230.
Brodin MB. Inflammatory bowel disease and isotretinoin. J Am Acad Dermatol. 1986;14(5 Pt 1):843. DOI: 10.1016/s0190-9622(86)80535-7. PMID: 2940270.
Radmanesh M. Anal fissure, rectal bleeding and proctitis as complications of systemic isotretinoin therapy: report of two cases. J Eur Acad Dermatol Venereol. 2006;20(10):1394. DOI: 10.1111/j.1468-3083.2006.01759.x. PMID: 17062102.
James WD, Berger TG, Elston DM. Andrews' Diseases of the Skin: Clinical Dermatology, (11th Ed.). Philadelphia, Elsevier, 2011:228e34.
Dubeau MF, Iacucci M, Beck PL, et al. Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis. 2012;19(2):445-456. DOI: 10.1002/ibd.22990. PMID: 22573536.
Bremner JD, Shearer KD, McCaffery PJ: Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry. 2012; 73(1):37-50. DOI: 10.4088/JCP.10r05993. PMID: 21903028. PMCID: PMC3276716.
Rademaker M. Adverse effects of isotretinoin: A restrospective review of 1743 patients started on isotretinoin. Australas J Dermatol. 2010;51(4):248-253. DOI: 10.1111/j.1440-0960.2010.00657.x. PMID: 21198520.
Katsambas A, Papakonstantinou A. Acne: Systemic treatment. Clin Dermatol. 2004; 22(5):412-418. DOI: 10.1016/j.clindermatol.2004.03.014. PMID: 15556728.
Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther. 2017;30(4). DOI: 10.1111/dth.12483. PMID: 28295859.
Prevost N, English JC. Isotretinoin: update on controversial issues. J Pediatr Adolesc Gynecol. 2013; 26(5):290-293. DOI: 10.1016/j.jpag.2013.05.007. PMID: 24147278.
Landis MN. Optimizing Isotretinoin Treatment of Acne: Update on Current Recommendations for Monitoring, Dosing, Safety, Adverse Effects, Compliance, and Outcomes. Am J Clin Dermatol. 2020;21(3):411-419. DOI: 10.1007/s40257-020-00508-0. PMID: 32107726.
Neudorfer M, Goldshtein I, Shamai-Lubovitz O, Chodick G,Dadon Y, Shalev V. Ocular adverse effects of systemic treatment with isotretinoin. Arch Dermatol. 2012;148(7):803-808. DOI: 10.1001/archdermatol.2012.352. PMID: 22508771.
Kaymak Y, Ilter N. The results and side effects of systemic isotretinoin treatment in 100 patients with acne vulgaris. Dermatol Nurs. 2006;18(6):576-580. PMID: 17286159.
Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2010;105(9):1986-1993. DOI: 10.1038/ajg.2010.124. PMID: 20354506. PMCID: PMC3073620.
Passier JL, Srivastava N, van Puijenbroek EP: Isotretinoin-induced inflammatory bowel disease. Neth J Med. 2006;64(2):52-54. PMID: 16517990.
Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol. 2013; 133(4):907-912. DOI: 10.1038/jid.2012.387. PMID: 23096714. PMCID: PMC3728031.
Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013;149(2):216-220. DOI: 10.1001/jamadermatol.2013.1344. PMID: 23426479.
Rashtak S, Khaleghi S, Pittelkow MR, Larson JJ, Lahr BD, Murray JA. Isotretinoin exposure and risk of inflammatory bowel disease. JAMA Dermatol. 2014;150(12):1322-1326. DOI: 10.1001/jamadermatol.2014.1540. PMID: 25207875.
Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol. 2009;104(11):2774-2778. DOI: 10.1038/ajg.2009.417. PMID: 19623167.
Brito Mde F, Sant’Anna IP, Galindo JC, Rosendo LH, Santos JB. Evaluation of clinical adverse eff ects and laboratory alterations in patients with acne vulgaris treated with oral isotretinoin. A Bras Dermatol. 2010;-85(3):331-337. DOI: 10.1590/s0365-05962010000300006. PMID: 20676466.
Menteş B, Leventoğlu S. Anal Fissür. In: Menteş B, Leventoğlu A, eds. Anorektal Bölgenin Selim Hastalıkları. İstanbul; Türk Kolon ve Rektum Cerrahisi Derneği. 2011:37-53.
Schlichtemeier S, Engel A. Anal fissure. Aust Prescr. 2016;39(1):14-17. DOI: 10.18773/austprescr.2016.007. PMID: 27041801. PMCID: PMC4816871.
Kenny SE, Irvine T, Driver CP, et al. Double blind randomised controlled trial of topical glyceryl trinitrate in anal fissure. Arch Dis Child. 2001;85(5):404-407. DOI: 10.1136/adc.85.5.404. PMID: 11668104. PMCID: PMC1718983.
Erpolat S, Gorpelioglu C, Sarifakioglu E. Isotretinoin associated anal fissure and rectal bleeding: a rare complication. Int J Dermatol. 2012;51(3):358-359. DOI: 10.1111/j.1365-4632.2010.04556.x. PMID: 22348579.
Güngör S, Gökdemir G. Anal fissure and rectal bleeding as a complication of systemic isotretinoin therapy: dermatologists know this side-effect, what about proctologists? Colorectal Dis. 2013;15(9):1187-1188. DOI: 10.1111/codi.12294. PMID: 23701373.
Karadağ AS, Çalka Ö, Akdeniz N. Evaluation of Side Effects of Isotretinoin in 150 Patients with Acne Vulgaris. Turkderm-Turk Arch Dermatol Venereol. 2011;45(1):37-42. DOI: 10.4274/turkderm.45.09.
Çıkım AÇ, Muammer Seyhan M. Efficiency and side effects of isotretinoin usage in the treatment of acne vulgaris. Türkderm. 2008;42:51-55.
Published
Issue
Section
License
Copyright (c) 2023 Hamza Aktaş, Zeynep Şener Bahçe
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
